BACKGROUND: This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma. METHODS: Patients with ovarian carcinoma treated at our hospital between 2000 and 2017 were identified. The risk factors of TEEs, including venous TEEs and arterial TEEs, and the association between TEEs and prognosis were investigated. Patients with TEEs were classified into two groups: those with severe TEEs, defined as patients who required urgent treatment for deep vein thrombosis, massive pulmonary embolism, acute myocardial infarction, and symptomatic cerebral infarction, and those with mild TEEs. The risk factors of severe TEEs and the association between severe TEEs and prognosis were investigated. RESULTS: A total of 369 patients were enrolled. Among them, 53 patients (14.4%) were complicated with TEEs. Clear cell carcinoma (CCC) was a greater risk factor of TEEs than serous carcinoma (hazard ratio [HR] = 2.81, p = 0.03). In multivariate analysis for survival, TEEs were a prognostic factor of poor progression-free survival (PFS; HR = 2.90, p < 0.01) and overall survival (OS; HR = 2.89, p < 0.01). Among 53 patients with TEEs, 17 (32.1%) developed severe TEEs. CCC was strongly associated with severe TEEs (HR = 42.6, p = 0.02). Multivariate analysis for survival demonstrated that severe TEEs were a risk factor of worse PFS (HR = 4.34, p < 0.01) and OS (HR = 3.30, p = 0.03). CONCLUSION: TEEs induced poor prognosis and was associated with CCC. A standard treatment for CCC should be included in the strategy of TEEs.
BACKGROUND: This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma. METHODS:Patients with ovarian carcinoma treated at our hospital between 2000 and 2017 were identified. The risk factors of TEEs, including venous TEEs and arterial TEEs, and the association between TEEs and prognosis were investigated. Patients with TEEs were classified into two groups: those with severe TEEs, defined as patients who required urgent treatment for deep vein thrombosis, massive pulmonary embolism, acute myocardial infarction, and symptomatic cerebral infarction, and those with mild TEEs. The risk factors of severe TEEs and the association between severe TEEs and prognosis were investigated. RESULTS: A total of 369 patients were enrolled. Among them, 53 patients (14.4%) were complicated with TEEs. Clear cell carcinoma (CCC) was a greater risk factor of TEEs than serous carcinoma (hazard ratio [HR] = 2.81, p = 0.03). In multivariate analysis for survival, TEEs were a prognostic factor of poor progression-free survival (PFS; HR = 2.90, p < 0.01) and overall survival (OS; HR = 2.89, p < 0.01). Among 53 patients with TEEs, 17 (32.1%) developed severe TEEs. CCC was strongly associated with severe TEEs (HR = 42.6, p = 0.02). Multivariate analysis for survival demonstrated that severe TEEs were a risk factor of worse PFS (HR = 4.34, p < 0.01) and OS (HR = 3.30, p = 0.03). CONCLUSION: TEEs induced poor prognosis and was associated with CCC. A standard treatment for CCC should be included in the strategy of TEEs.
Authors: K Kröger; D Weiland; C Ose; N Neumann; S Weiss; C Hirsch; K Urbanski; S Seeber; M E Scheulen Journal: Ann Oncol Date: 2005-11-09 Impact factor: 32.976
Authors: Jermaine Coward; Hagen Kulbe; Probir Chakravarty; David Leader; Vessela Vassileva; D Andrew Leinster; Richard Thompson; Tiziana Schioppa; Jeffery Nemeth; Jessica Vermeulen; Naveena Singh; Norbert Avril; Jeff Cummings; Elton Rexhepaj; Karin Jirström; William M Gallagher; Donal J Brennan; Iain A McNeish; Frances R Balkwill Journal: Clin Cancer Res Date: 2011-07-27 Impact factor: 12.531
Authors: Zhenfeng Duan; Rosemary Foster; Debra A Bell; Jennifer Mahoney; Kathryn Wolak; Ami Vaidya; Constanze Hampel; Hang Lee; Michael V Seiden Journal: Clin Cancer Res Date: 2006-09-01 Impact factor: 12.531
Authors: K Uno; S Homma; T Satoh; K Nakanishi; D Abe; K Matsumoto; A Oki; H Tsunoda; I Yamaguchi; T Nagasawa; H Yoshikawa; K Aonuma Journal: Br J Cancer Date: 2007-01-09 Impact factor: 7.640
Authors: T Satoh; A Oki; K Uno; M Sakurai; H Ochi; S Okada; R Minami; K Matsumoto; Y O Tanaka; H Tsunoda; S Homma; H Yoshikawa Journal: Br J Cancer Date: 2007-09-25 Impact factor: 7.640
Authors: A J Muñoz; M de Toro; L Ortega; C López; A Gutiérrez; D S Juliao; M Arregui; N Lobato; I Echavarría; I Márquez-Rodas; M Martín Journal: Clin Transl Oncol Date: 2021-08-09 Impact factor: 3.405